REGENERON PHARMACEUTICALS, INC.·4

Feb 12, 4:02 PM ET

Fenimore Christopher R. 4

4 · REGENERON PHARMACEUTICALS, INC. · Filed Feb 12, 2024

Insider Transaction Report

Form 4
Period: 2024-02-09
Transactions
  • Sale

    Common Stock

    2024-02-09$954.57/sh1,100$1,050,02714,972 total
  • Sale

    Common Stock

    2024-02-09$950.49/sh344$326,96918,947 total
  • Sale

    Common Stock

    2024-02-09$951.39/sh487$463,32718,460 total
  • Sale

    Common Stock

    2024-02-09$952.62/sh1,046$996,44117,414 total
  • Sale

    Common Stock

    2024-02-09$953.47/sh1,342$1,279,55716,072 total
  • Sale

    Common Stock

    2024-02-09$955.00/sh600$573,00014,372 total
Holdings
  • Common Stock

    (indirect: 2022 GRAT)
    4,269
  • Common Stock

    (indirect: By Trust)
    1,897
  • Common Stock

    (indirect: By Trust)
    460
  • Common Stock

    (indirect: 2021 GRAT)
    1,473
  • Common Stock

    (indirect: By 401(k))
    1,499
  • Common Stock

    (indirect: By Trust)
    461
Footnotes (6)
  • [F1]Represents volume-weighted average price of sales of 344 shares of Company stock on February 9, 2024 at prices ranging from $950.33 to $950.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
  • [F2]Represents volume-weighted average price of sales of 487 shares of Company stock on February 9, 2024 at prices ranging from $951.03 to $951.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
  • [F3]Represents volume-weighted average price of sales of 1,046 shares of Company stock on February 9, 2024 at prices ranging from $952.11 to $952.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
  • [F4]Represents volume-weighted average price of sales of 1,342 shares of Company stock on February 9, 2024 at prices ranging from $953.02 to $953.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
  • [F5]Represents volume-weighted average price of sales of 1,100 shares of Company stock on February 9, 2024 at prices ranging from $954.00 to $954.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
  • [F6]These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT